Liquidia Corporation (LQDA)
Free
No email, no account, no signup.
Pulling latest news for Liquidia Corporation…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Pulmonary hypertension treatments
Market Cap
$3.6B
Market sentiment
Sentiment has improved sharply after a clear revenue/EPS beat, continued patient growth, and a third consecutive profitable quarter; however, discussion still highlights the patent litigation as the main uncertainty.
Why BUY ?
Operational performance (rapid sequential sales growth, profitability, and rising cash) reduces financing risk and strengthens the bull case. A material binary risk remains from the patent litigation, supporting a measured add rather than an aggressive increase.
- Consider adding in tranches (e.g., 1/3–1/2 of the intended add now and the remainder after legal/commercial updates), with a defined risk budget due to injunction risk.
We're already tracking Liquidia Corporation — here are the latest events we've registered
Recent News
- Since 2026-05-14, there have been no new company press releases or FDA/clinical milestone announcements. On May 15, filings showed CEO Roger Jeffs sold 75,000 shares (May 13–15) under a pre-arranged Rule 10b5-1 plan (~$4.3M, price range $53.99–$59.64). On May 19, management presented at the H.C. Wainwright 4th Annual Bioconnect, and new 13F filings indicated multiple institutions increased positions (including GSA Capital Partners). The stock continued higher and printed a new 52-week high around May 19 (close ~ $59.98). The United Therapeutics patent dispute over YUTREPIA remains the key risk.
Want to know how this news affects Liquidia Corporation? Order the analysis.
Order analysis – Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Liquidia Corporation will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.